Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of ₹63,318 Crore up from ₹57,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to ₹56,009 Crore. Consolidated Net Profit of ₹11,142 up 12% from ₹9,958 Crore in the same quarter of the previous year. The Earnings per Share is ₹66.98 in this quarter.
Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%
Related Post
- Sula Vineyards Limited posts lower Q3 FY26 profit as tactical destocking hits margins; wine tourism revenue rises
Sula Vineyards Limited (NSE: SULA, BSE: 543711) reported lower profit for the quarter ended Dec.…
-
Filatex India Limited posts stable Q3 FY26 revenue as margins improve on product mix and efficiency gains
Filatex India Limited (NSE: FILATEX, BSE: 526227) reported stable revenue and improved profitability for the…
-
Man Industries (India) Limited reports strong Q3 FY26 earnings as margins expand and order book rises
Man Industries (India) Limited (NSE: MANINDS, BSE: 513269) reported a sharp increase in revenue, profit…